Page 333 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

References
1. Tuchman M, Stoeckeler JS, Kiang DT, O’Dea RF, Ramnaraine ML, Mirkin BL. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med. 1985;313(4):245-249.
2. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin
Invest. 1988;81(1):47-51.
3. Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine
dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer.
1991;68(3):499-501.
4. van Gennip AH, Abeling NG, Stroomer AE, van Lenthe H, Bakker HD. Clinical and biochemical findings
in six patients with pyrimidine degradation defects. J Inherit Metab Dis. 1994;17(1):130-132.
5. van Gennip AH, Abeling NG, Vreken P, van Kuilenburg ABP. Inborn errors of pyrimidine degradation: clinical, biochemical and molecular aspects. J Inherit Metab Dis. 1997;20(2):203-213.
6. Brockstedt M, Jakobs C, Smit LM, van Gennip AH, Berger R. A new case of dihydropyrimidine
dehydrogenase deficiency. J Inherit Metab Dis. 1990;13(1):121-124.
7. Henricks LM, Opdam FL, Beijnen JH, Cats A, Schellens JHM. DPYD genotype-guided dose
individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label
update. Ann Oncol. 2017;28(12):2915-2922.
8. Van Kuilenburg ABP, Van Lenthe H, Tromp A, Veltman PC, Van Gennip AH. Pitfalls in the diagnosis of
patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem. 2000;46(1):9-17.
9. Coenen MJH, Paulussen ADC, Breuer M, et al. Evolution of Dihydropyrimidine Dehydrogenase
Diagnostic Testing in a Single Center during an 8-Year Period of Time. Current therapeutic
research, clinical and experimental. 2019;90:1-7.
10. Jacobs BAW, Deenen MJ, Pluim D, et al. Pronounced between-subject and circadian variability
in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human
volunteers. Br J Clin Pharmacol. 2016;82(3):706-716.
11. Grem JL, Yee LK, Venzon DJ, Takimoto CH, Allegra CJ. Inter- and intraindividual variation in
dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer
13
General discussion
Chemother Pharmacol. 1997;40(2):117-125.
12. Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB. Comparative functional
analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase
activity. Cancer Res. 2014;74(9):2545-2554.
13. Bosch TM, Bakker R, Schellens JH, Cats A, Smits PH, Beijnen JH. Rapid detection of the DPYD
IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity. Mol Diagn
Ther. 2007;11(2):105-108.
14. Deenen MJ, Meulendijks D, Cats A, et al. Upfront Genotyping of DPYD*2A to Individualize
Fluoropyrimidine Therapy: A Safety and Cost Analysis. J Clin Oncol. 2016;34(3):227-234.
15. Henricks LM, Lunenburg CATC, de Man FM, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol.
2018;19(11):1459-1467.
16. Henricks LM, Lunenburg CATC, de Man FM, et al. A cost analysis of upfront DPYD genotype-guided
dose individualisation in fluoropyrimidine-based anticancer therapy. Eur J Cancer. 2018;107:60- 67.
331